- Risk of bDMARD withdrawal higher for TNFi monotherapy compared w/ cs/bDMARD combination - If monotherapy necessary, etanercept should be preferred over infliximab and adalimumab Silvagni E et al. BMJ Open 2018 #ACR19 @RheumNow

RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Sanofi Genzyme and Regeneron. All content chosen by RheumNow and its faculty.

SLE uncommonly has ILD in clinical practice. 2% had ILD usually mild and non progressive abstr 1563 #ACR #ACR19 @RheumNow #SLE https://t.co/CWgdfEQZ27

Prednisone is associated with organ damage in SLE. Chicken or egg argument? Bad lupus gets more steroids and more damage AND steroids independently increase CV events and other damage ex OP and cataracts #ACR19 @RheumNow abstr 2562 #SLE https://t.co/onEII3OKhS

Abstract #1759 MTX did not demonstrate superior efficacy over placebo on pain and function at 3 and 12 months Erosive Hand OA (EHOA). MTX significantly reduced the progression of joint damage compared to placebo #ACR19 @RheumNow Do you use MTX in EHOA?

A short piece I wrote for @RheumNow on classification criteria and their role in diagnosis / clinical practice 1. These are meant for research! 2. We use them for diagnosis anyway... 3. Remember their limitations when doing so! @RheumNow https://t.co/SSr28zkc0U https://t.co/EDzgWPIxXe

• When Classification and Diagnosis Diverge | ACR19 Coverage by RheumNow

Great talk by Dr. Manzi for Year in Review! See my recent podcast about SPIRIT-H2H. It shows that IXE > ADA for skin but NOT for joints. @RheumNow #ACR19 https://t.co/FzY8O7KX1A

• Mike Putman on Twitter: "IL17i or TNFi in psoriatic arthritis? Should RCTs…

It's Dr. Paul Sufka @psufka talking about methotrexate and prednisone for Hand osteoarthritis https://t.co/jRwWgzVvPx #ACR19 @rheumnow

• Methotrexate and Prednisone for Hand OA: Dr. Paul Sufka - YouTube

This is an excellent review by @BolekBerqui on the use of social media. Great quote “We can think of the internet like the medical elevator” #ACR19 #ACRBest @RheumNow https://t.co/CNzVtrFgr2

• Jilaine Berquist on Twitter: "Thanks @ACRheum for featuring my talk. When …

BK virus bite Mia was not increased in CTD or drug use. Safe and reassuring and different from cornyviris which is increased with Rituximab but small study. Maybe underpowered #ACR19 @RheumNow abstr 2115 https://t.co/8z77Pxgp3E

#ACR19 Year in Review: Important trial in APLS this year demonstrating to me that DOACs should clearly not be used in this disease state. Rate of stroke 19% in rivaroxaban vs. 3% in warfarin. @RheumNow https://t.co/YkXRg0J944

#ACR19 Year in Review: Dr. Manzi Re: Medical Cannabis - "Bottom line is that it's here and our patients are ordering it off Amazon." This has been my experience as well! Need high quality studies to know the possible risks and benefits @RheumNow https://t.co/k8we1HWfkk

Does VTE increase risk of subsequent MACE (cardiac events ie MI). National Data Bank excluded pts with past CV events. 2X risk of future CVE post VTE. Strange as risks are a bit different #ACRbest #ACR19 @RheumNow abst196 https://t.co/XoSkow7AAQ

Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients With Active AS • Onset of response to upadacitinib 15 mg QD tx was rapid • AEs similar between upadacitinib and placebo #ACR19 @RheumNow

Abstr#2273: higher placental transfer antiTNFs=ADA,IFX,GOL. Less transfer=CTZ,ETN. No ⬆️ in infxns in offspring, even with 3rd tri exposure. Potential trend for ⬆️ in serious infxns (>/=1 hosp adm 1st yr of life) with high placental transfer antiTNFs, not sig. #ACR2019 @RheumNow https://t.co/qEIl9lxlv1